Abstract:The application of population approaches to drug development is recommended in several US Food and Drug Administration (Fl)A) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge. upon drug Safety and efficacy. This article briefly discusses the 2-stage approach to the estimation of population pharmacokinetic parameters, which requires serial multiple measurements on each participant, and comprehensively reviews the nonlinear mixed-effects. modelling approach, which can be applied in situations where extensive sampling is not done on all or any of the participants.Certain preliminary information, such as the compartment model used in describing the pharmacokinetics of the drug, is required for a population pharmacokinetic study. The practical design considerations of the location of sampling times, number of samples/participants and the need to sample an individual more than once should be borne in mind. Simulation may be useful for choosing the study design that will best meet study objectives.The objectives of the population pharmacokinetic study can be secondary to the objectives of the primary clinical study lin which case an add-on population pharmacokinetic protocol may be needed) or primary (when a stand-alone protocol is required). Having protocols for population pharmacokinetic studies is an integral part of 'good pharmacometric practice'.Real-time data assembly and analysis permit an ongoing evaluation of site compliance with the study protocol and provide the opportunity to correct violations of study procedures. Adequate policies and procedures should be in place for study blind maintenance. Real-time data assembly creates the opportunity for detecting and correcting errors in concentration-time data, drug administration history and covariate data.Population pharmacokinetic analyses may be undertaken in 3 interwoven steps: exploratory data analysis, model development and model validation (i.e. predictive performance). Documentation for regulatory purposes should include a complete inventory of key runs in the analyses undertaken (with flow diagrams if possible), accompanied by articulation of objectives, assumptions and hypotheses. Use of diagnostic analyses of goodness of fit as evidence of reliability of results is advised. Finally, the use of stability testing or model validation may be warranted to support label claims.The opinions expressed in this article were revised by incorporating comments from various sources and published by the FDA as 'Guidance for Industry: Population Pharmacokinetics' (see the FDA home page http://www.fda.gov for further information).

Application of machine learning techniques in population pharmacokinetics/pharmacodynamics modeling

Application of machine learning techniques to the analysis and prediction of drug pharmacokinetics

Population pharmacokinetic model selection assisted by machine learning

Adapting physiologically-based pharmacokinetic models for machine learning applications

The Use of Population Pharmacokinetics in Drug Development

Adoption of Machine Learning in Pharmacometrics: An Overview of Recent Implementations and Their Considerations

Applications of machine learning in metabolomics: Disease modeling and classification

Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model‐Informed Precision Medicine

A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans

Data-Driven Clinical Pharmacy Research: Utilizing Machine Learning and Medical Big Data

Simulating realistic patient profiles from pharmacokinetic models by a machine learning postprocessing correction of residual variability

[Population Pharmacokinetics and Its Application in New Drug Research].

Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice

Application of machine learning combined with population pharmacokinetics to improve individual prediction of vancomycin clearance in simulated adult patients

Population Pharmacokinetics - A Regulatory Perspective

Applications of Machine Learning in Pharmacogenomics: Clustering Plasma Concentration-Time Curves

Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models

Machine learning advances the integration of covariates in population pharmacokinetic models: Valproic acid as an example

Applications of machine learning in drug discovery and development

Machine Learning Applications in Drug Discovery

Machine Learning Approaches and their Applications in Drug Discovery and Design